

INFORMATION DISCLOSURE CITATION

Docket No.: RLL-313US

Serial No.: 10/552,322

Applicants: MEHTA *et al.*

Filed: 10/7/2005

Group:

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	4,801,600	1/31/1989	Wang <i>et al.</i>	514	376	
	A2	4,921,869	5/1/1990	Wang <i>et al.</i>	514	376	
	A3	5,254,577	10/19/1993	Carlson <i>et al.</i>	514	376	
	A4	5,547,950	8/20/1996	Hutchinson <i>et al.</i>	514	252	
	A5	5,700,799	12/23/1997	Hutchinson <i>et al.</i>	514	235.8	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	B1	EP 0 312 000	4/19/1989	EPO	C07D	263/20	
	B2	EP 0 352 781	1/31/1990	EPO	C07D	263/20	
	B3	JP 11-322729	11/24/1999	Japan	C07D	263/20	
	B4	WO 90/02744	3/22/1990	PCT	C07D	413/04	
	B5	WO 93/09103	5/13/1993	PCT	C07D	263/20	
	B6	WO 93/23384	11/25/1993	PCT	C07D	263/20	
	B7	WO 99/64417	12/16/1999	PCT	C07D	413/14	
	B8	WO 00/21960	4/20/2000	PCT	C07D	413/14	
	B9	WO 02/06278	1/24/2002	PCT	C07D	413/14	
	B10	WO 02/51819	7/4/2002	PCT	C07D	263/24	
	B11	WO 03/07870	1/30/2003	PCT	A61K		
	B12	WO 03/27083	4/3/2003	PCT	C07D	263/24	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	C1	Antibacterial & Antifungal Drug Discovery & Development Summit, Strategic Research Institute, June 28-29, 2001, Amsterdam, The Netherlands
	C2	Pae <i>et al.</i> , "Synthesis and <i>In Vitro</i> Activity of New Oxazolidinone Antibacterial Agents Having Substituted Isoxazoles", <i>Bioorganic & Medicinal Chemistry Letters</i> , 9(18):2679-2684 (1999)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

Docket No.: RLL-313US

Serial No.: 10/552,322

Applicants: MEHTA et al.

Filed: 10/7/2005

Group:

C3	Park and Britteli et al, "Antibacterials. Synthesis and Structure-Activity Studies of 3-Aryl-2-oxooxazolidines. 4. Multiply-Substituted Aryl Derivatives". <i>Journal of Medicinal Chemistry</i> , <u>35</u> (6):1156-1165 (1992)
C4	Tokuyama et al, "Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 1. Conversion of 5-Substituent on Oxazolidinone", <i>Chemical and Pharmaceutical Bulletin</i> , <u>49</u> (4):347-352 (2001)
C5	Tokuyama et al, "Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. ¹⁾ Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones", <i>Chemical and Pharmaceutical Bulletin</i> , <u>49</u> (4):353-360 (2001)
C6	Tokuyama et al, "Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 3. ¹⁾ Synthesis and Evaluation of 5-Thiocarbamate Oxazolidinones", <i>Chemical and Pharmaceutical Bulletin</i> , <u>49</u> (4):361-367 (2001)
C7	Yu and Huiyan, "Synthesis and Antibacterial Activity of Linezolid Analogues," <i>Bioorganic & Medicinal Chemistry Letters</i> , <u>12</u> (6):857-859 (2002)
C8	Gordeev, "Combinational lead discovery and optimization of antimicrobial oxazolidinones", <i>Current Opinion in Drug Discovery & Development</i> , <u>4</u> (4):450-461 (2001)
C9	Gregory et al., "Antibacterials. Synthesis and Structure-Activity Studies of 3-Aryl-2-oxooxazolidines. 1. The "B" Group", <i>Journal of Medicinal Chemistry</i> , <u>32</u> (8):1673-1681 (1989)
C10	Gregory et al., "Antibacterials. Synthesis and Structure-Activity Studies of 3-Aryl-2-oxooxazolidines. 2. The "A" Group", <i>Journal of Medicinal Chemistry</i> , <u>33</u> (9):2569-2578 (1990)
C11	Posters No. 1822-1834, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000, Toronto, Canada
C12	Posters No. 1023, 1040-1051, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, September 22-25, 2001, Chicago, USA
C13	Wang et al., "Chiral Synthesis of DUP 721, a New Antibacterial Agent ¹⁾ ", <i>Tetrahedron</i> , <u>45</u> (5):1323-1326 (1989)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

PAGE 2 OF 2